{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:20:37Z","timestamp":1781716837292,"version":"3.54.5"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>The usual adverse events of amantadine are dizziness, dry mouth, and peripheral edema. Postmarketing experience has revealed abnormal movements such as tremors, involuntary muscle contractions, and gait abnormalities. Herein, we report a case of an elderly male who presented with generalized twitching associated with amantadine. A 64-year-old male presenting with jerking movements within one day of onset was admitted. Sudden and involuntary distal lower and upper limb muscle twitching was observed. The subject presented subsequent brief movements when attempting to stand or hold arms antigravity. He was diagnosed with Parkinson\u2019s disease three years ago. Eight days before the presentation to the emergency department, he consulted with his primary care physician, who prescribed amantadine to improve his motor symptoms. On the seventh day, he developed brisk abnormal movements. Laboratory exams, neuroimaging, and electroencephalogram were unremarkable. Amantadine was discontinued. After three days, the patient reported that his jerking movements had fully recovered. To the authors\u2019 knowledge, 22 individuals with amantadine-associated myoclonus had already been reported in the literature. The pathophysiology of amantadine-induced myoclonus is probably related to serotoninergic pathways. Myoclonus secondary to amantadine was slightly more common in men. The population affected was elderly, with a mean and median age of 67.7 and 64 years.<\/jats:p>","DOI":"10.3390\/clinpract13040075","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T02:04:04Z","timestamp":1689905044000},"page":"830-837","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Myoclonus Secondary to Amantadine: Case Report and Literature Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-2177","authenticated-orcid":false,"given":"Jamir Pitton","family":"Rissardo","sequence":"first","affiliation":[{"name":"Medicine Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8024-2354","authenticated-orcid":false,"given":"Ana Let\u00edcia","family":"Fornari Caprara","sequence":"additional","affiliation":[{"name":"Medicine Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_2","first-page":"381","article-title":"Edema and myoclonus in a patient with Parkinson\u2019s disease treated by amantadine","volume":"6","author":"Chevalier","year":"1980","journal-title":"L\u2019encephale"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s40263-021-00862-5","article-title":"Amantadine Revisited: A Contender for Initial Treatment in Parkinson\u2019s Disease?","volume":"35","author":"Marmol","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mds.870110123","article-title":"Amantadine-induced \u201cvocal\u201d myoclonus","volume":"11","author":"Pfeiffer","year":"1996","journal-title":"Mov. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.56.2.279","article-title":"Amantadine-induced cortical myoclonus","volume":"56","author":"Matsunaga","year":"2001","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000095147","article-title":"Severe reversible neurological complications following amantadine treatment in three elderly patients with renal insufficiency","volume":"56","author":"Nakata","year":"2006","journal-title":"Eur. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112.e5-6","DOI":"10.1016\/j.ajem.2007.07.015","article-title":"Amantadine-induced serotonin syndrome in a patient with renal failure","volume":"26","author":"Cheng","year":"2008","journal-title":"Am. J. Emerg. Med."},{"key":"ref_8","first-page":"109","article-title":"Fatal intoxication using amantadine and pramipexole in a uremic patient","volume":"17","author":"Hong","year":"2008","journal-title":"Acta Neurol. Taiwan."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","article-title":"Plasma amantadine concentrations in patients with Parkinson\u2019s disease","volume":"15","author":"Nishikawa","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/mds.23140","article-title":"Drug-induced cranial myoclonus","volume":"25","author":"Gupta","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_11","first-page":"493","article-title":"A Case of Subacute Encephalopathy, Ataxia and Myoclonus Due to Amantadine Toxicity in Chronic Renal Insufficiency","volume":"25","author":"Hardwick","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ageing\/afs043","article-title":"Amantadine-induced myoclonus in a patient with progressive supranuclear palsy","volume":"41","author":"Yarnall","year":"2012","journal-title":"Age Ageing"},{"key":"ref_13","first-page":"62","article-title":"A case of progressive supranuclear palsy with cortical myoclonus","volume":"4","author":"Kawamura","year":"2013","journal-title":"Tokushima"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00415-015-7771-y","article-title":"Clinical and electroencephalographic on-off effect of amantadine in chronic non-traumatic minimally conscious state","volume":"262","author":"Estraneo","year":"2015","journal-title":"J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00415-016-8357-z","article-title":"The clinical heterogeneity of drug-induced myoclonus: An illustrated review","volume":"264","author":"Janssen","year":"2017","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20170017","DOI":"10.2490\/prm.20170017","article-title":"Case Reports Describing Amantadine Intoxication in a Rehabilitation Hospital","volume":"2","author":"Kunieda","year":"2017","journal-title":"Prog. Rehabil. Med."},{"key":"ref_17","first-page":"100045","article-title":"High dose amantadine therapy may cause increased falling in patients with Parkinson\u2019s disease: A case report","volume":"3","author":"Dames","year":"2020","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/0897190021997003","article-title":"Amantadine Associated Myoclonus: Case Report and Review of the Literature","volume":"34","author":"Poon","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113443","DOI":"10.1016\/j.bbr.2021.113443","article-title":"Involvement of dopamine D(2) and glutamate NMDA receptors in the antidepressant-like effect of amantadine in mice","volume":"413","author":"Dias","year":"2021","journal-title":"Behav. Brain Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0773.1971.tb00646.x","article-title":"Further studies on the mode of action of amantadine","volume":"30","author":"Svensson","year":"1971","journal-title":"Acta Pharmacol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.0953-816X.2004.03297.x","article-title":"Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine","volume":"19","author":"Peeters","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.neuropharm.2010.10.008","article-title":"Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1\/GluN2A NMDARs","volume":"60","author":"Otton","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Krzystanek, M., and Pa\u0142asz, A. (2020). Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression\u2014Case Series Study. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100326"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(73)90224-0","article-title":"Effects of amantadine and amphetamine on serotonin uptake and release by human blood platelets","volume":"21","author":"Lemmer","year":"1973","journal-title":"Eur. J. Pharmacol."},{"key":"ref_25","first-page":"307","article-title":"The serotonin hypothesis of myoclonus from the perspective of neuronal rhythmicity","volume":"89","author":"Welsh","year":"2002","journal-title":"Adv. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/bc.bc_77_21","article-title":"Lithium-associated movement disorder: A literature review","volume":"8","author":"Rissardo","year":"2022","journal-title":"Brain Circ."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rissardo, J.P., and Caprara, A.L.F. (2023). Fluoroquinolone-Associated Movement Disorder: A Literature Review. Medicines, 10.","DOI":"10.3390\/medicines10060033"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1211\/0022357001774390","article-title":"N-Methyl-D-aspartate receptor antagonists enhance the head-twitch response, a 5-hydroxytryptamine2 receptor-mediated behaviour, in reserpine-treated mice","volume":"52","author":"Kim","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s13311-020-00922-6","article-title":"Physiology-Based Treatment of Myoclonus","volume":"17","author":"Pena","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.7326\/0003-4819-94-4-454","article-title":"Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function","volume":"94","author":"Horadam","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.28.2.216","article-title":"Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults","volume":"28","author":"Hayden","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00002826-198406000-00005","article-title":"In vitro binding of amantadine to plasma proteins","volume":"7","author":"Liu","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00314331","article-title":"Amantadine sulphate in treating Parkinson\u2019s disease: Clinical effects, psychometric tests and serum concentrations","volume":"236","author":"Brenner","year":"1989","journal-title":"J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/bms.1200120910","article-title":"A revision of the metabolic disposition of amantadine","volume":"12","author":"Tenczer","year":"1985","journal-title":"Biomed. Mass. Spectrom."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00023210-200418020-00003","article-title":"Drug-induced myoclonus: Frequency, mechanisms and management","volume":"18","author":"Puertas","year":"2004","journal-title":"CNS Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1532-5415.1990.tb03541.x","article-title":"Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home","volume":"38","author":"Degelau","year":"1990","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/WNL.50.5.1456","article-title":"Acute delirium after withdrawal of amantadine in Parkinson\u2019s disease","volume":"50","author":"Factor","year":"1998","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/13\/4\/75\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:15:56Z","timestamp":1760127356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/13\/4\/75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["clinpract13040075"],"URL":"https:\/\/doi.org\/10.3390\/clinpract13040075","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}